WO2003025119A3 - Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies - Google Patents
Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies Download PDFInfo
- Publication number
- WO2003025119A3 WO2003025119A3 PCT/US2002/024154 US0224154W WO03025119A3 WO 2003025119 A3 WO2003025119 A3 WO 2003025119A3 US 0224154 W US0224154 W US 0224154W WO 03025119 A3 WO03025119 A3 WO 03025119A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- enhance
- receptor
- immunostimulatory oligonucleotides
- mediated
- Prior art date
Links
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- 102000009109 Fc receptors Human genes 0.000 title 1
- 108010087819 Fc receptors Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 230000030741 antigen processing and presentation Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02759219A EP1501359A4 (en) | 2001-08-03 | 2002-07-30 | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
JP2003529893A JP2005518343A (en) | 2001-08-03 | 2002-07-30 | Novel PGC-1 isoforms and their use to improve use-mediated immunotherapy |
CA002456193A CA2456193A1 (en) | 2001-08-03 | 2002-07-30 | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31043701P | 2001-08-03 | 2001-08-03 | |
US60/310,437 | 2001-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003025119A2 WO2003025119A2 (en) | 2003-03-27 |
WO2003025119A3 true WO2003025119A3 (en) | 2004-12-02 |
Family
ID=23202486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024154 WO2003025119A2 (en) | 2001-08-03 | 2002-07-30 | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030072762A1 (en) |
EP (1) | EP1501359A4 (en) |
JP (1) | JP2005518343A (en) |
CA (1) | CA2456193A1 (en) |
WO (1) | WO2003025119A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
MXPA05004588A (en) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection. |
AU2003300919A1 (en) | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
AU2004241093B2 (en) * | 2003-05-16 | 2009-08-27 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
US20060121023A1 (en) * | 2004-12-07 | 2006-06-08 | George Weiner | Method to decrease nonspecific staining by Cy5 |
CN1810970B (en) * | 2005-01-27 | 2011-05-18 | 长春华普生物技术有限公司 | CpG-containing single-stranded deoxynucleotide, its vaccine composition and their application |
JP5659332B2 (en) | 2008-06-27 | 2015-01-28 | ゾエティス・エルエルシー | Novel adjuvant composition |
PT2560658T (en) | 2010-04-21 | 2017-05-26 | Ventirx Pharmaceuticals Inc | Enhancing antibody-dependent cellular cytotoxicity |
JP5985481B2 (en) * | 2010-09-01 | 2016-09-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Rapid production of anti-idiotype antibodies |
KR102257743B1 (en) | 2013-09-19 | 2021-05-28 | 조에티스 서비시즈 엘엘씨 | Oil-based adjuvants |
PL3244920T3 (en) | 2015-01-16 | 2023-09-25 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
JP6602958B2 (en) * | 2015-05-20 | 2019-11-06 | イミュンワーク インク. | Molecular constructs having targeting and effector components and uses thereof |
WO2022192268A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863538A (en) * | 1992-03-05 | 1999-01-26 | Board Of Regents, The University Of Texas System | Compositions for targeting the vasculature of solid tumors |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248332B1 (en) * | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ES2267100T5 (en) * | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | IMMUNOMODULATING OLIGONUCLEOTIDES. |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AU4642600A (en) * | 1999-04-15 | 2000-11-02 | Regents Of The University Of California, The | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells |
US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
AU7013401A (en) * | 2000-06-22 | 2002-01-02 | Univ Iowa Res Found | Methods for enhancing antibody-induced cell lysis and treating cancer |
-
2002
- 2002-07-30 JP JP2003529893A patent/JP2005518343A/en not_active Abandoned
- 2002-07-30 US US10/209,070 patent/US20030072762A1/en not_active Abandoned
- 2002-07-30 WO PCT/US2002/024154 patent/WO2003025119A2/en not_active Application Discontinuation
- 2002-07-30 CA CA002456193A patent/CA2456193A1/en not_active Abandoned
- 2002-07-30 EP EP02759219A patent/EP1501359A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5863538A (en) * | 1992-03-05 | 1999-01-26 | Board Of Regents, The University Of Texas System | Compositions for targeting the vasculature of solid tumors |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
Non-Patent Citations (1)
Title |
---|
HEIJNEN ET AL: "A human Fc gamma RI/CD64 transgenic model for in vivo analysis of (bispecific) antibody therapeutics", JOURNAL OF HEMATOTHERAPY, vol. 4, no. 5, October 1995 (1995-10-01), pages 351 - 356, XP002982153 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003025119A2 (en) | 2003-03-27 |
EP1501359A4 (en) | 2007-04-18 |
CA2456193A1 (en) | 2003-03-27 |
US20030072762A1 (en) | 2003-04-17 |
JP2005518343A (en) | 2005-06-23 |
EP1501359A2 (en) | 2005-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003025119A3 (en) | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies | |
WO2003000187A3 (en) | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof | |
WO2004099249A3 (en) | Optimized fc variants and methods for their generation | |
EP2292271A3 (en) | Remodelling and glycoconjugation of an antibody | |
WO2003011115A3 (en) | Peptide-based multimeric targeted contrast agents | |
EP2345671B8 (en) | Optimized fc variants and methods for their generation | |
WO2003008583A3 (en) | Novel compositions and methods for cancer | |
WO2004064595A3 (en) | Multivalent constructs for therapeutic and diagnostic applications | |
WO2003029262A3 (en) | The human mob-5 (il-24) receptors and uses thereof | |
WO2001035991A3 (en) | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof | |
WO2005037190A3 (en) | Multiplex vaccines | |
WO2005032582A3 (en) | Immunogenic compositions for streptococcus pyogenes | |
WO2004099231A3 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
WO2002024792A3 (en) | Adhesive compositions including self-assembling molecules, adhesives, articles, and methods | |
DE60141773D1 (en) | GREAT SIMILAR RECEPTOR 5-LIGANDS AND USE PROCESS | |
WO2007133290A3 (en) | Anti-ox40l antibodies and methods using same | |
WO2000056360A3 (en) | Vaccine against antigens from bacteriae | |
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
WO2004091572A3 (en) | Cochleate compositions directed against expression of proteins | |
WO2001047959A3 (en) | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof | |
WO2004093808A3 (en) | Novel tumor-associated antigens | |
WO2003104425A3 (en) | Novel stable anti-cd22 antibodies | |
WO2003000186A3 (en) | Novel phenylamino-pyrimidines and uses thereof | |
WO2005037470A3 (en) | Encapsulated nanoparticles, products containing the same, and methods for using the same | |
WO2004005476A3 (en) | Nucleic acid compositions for stimulating immune responses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2456193 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002324569 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003529893 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002759219 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002759219 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002759219 Country of ref document: EP |